[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.176.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
September 23, 1974

Propranolol in the Management of Hypertension in a Long-Term Dialysis Program

Author Affiliations

From the Renal Division, Department of Medicine, Mt Sinai Hospital Medical Center, Chicago, and the University of Health Sciences, Chicago Medical School (Drs. Freedman and Smith).

JAMA. 1974;229(13):1777-1778. doi:10.1001/jama.1974.03230510051023
Abstract

IN patients with chronic renal failure requiring maintenance dialysis, hypertension is frequently difficult to control without bilateral nephrectomy. Because of surgical risks in uremic patients, and also because of the complicating postnephrectomy anemias and problems in fluid and electrolyte balance, it is desirable to avoid nephrectomy. This is true particularly in view of the observed occasional improvement in renal function after several months of dialysis.

Recently there have been reports on the value of propranolol hydrochloride in controlling severe hypertension in nonuremic patients.1 We are reporting a trial of this drug in patients with uremia.

Patients and Methods  Six of the 20 patients on the longterm dialysis program have had persistent hypertension, despite therapy with furosemide, methyldopa, hydralazine hydrochloride, and guanethidine sulfate, and rigorous control of sodium intake and weight gain between dialyses. Many were experiencing postural hypotensive effects, drowsiness, and impotence, and were therefore at the limit of

×